在哪里能买到日本阿那莫林？

Where to buy Japanese Anamorelin

Anamorelin was developed by Japan's Ono Pharmaceutical and was launched in Japan on January 22, 2021, which means patients can buy Anamorelin in Japan. In China, it is not yet on the market, and patients cannot buy it in domestic hospital pharmacies.

If it is inconvenient for patients to go abroad, they can also obtain them through professional domestic overseas medical service institutions. The drugs can be directly mailed to their homes from overseas. They are guaranteed to be genuine and at an affordable price. It also saves patients the trouble of going abroad to purchase drugs and reduces a considerable financial burden. This way of obtaining overseas drugs is more cost-effective. However, overseas drug prices are not fixed due to exchange rate fluctuations. It is recommended to consult customer service staff for specific costs and acquisition procedures.

The specification of Anamorelin Adlumiz is 50mg*100 capsules, the price is 4000$ per box, and the supply is 50 days.

The usual dose of Anamorelin for adults is 100 mg taken orally once a day on an empty stomach, which means you need to take 2 pills a day. One box can last for 50 days. Patients can choose the quantity they need to buy according to their own circumstances.

A multicenter, open-label, single-arm study enrolled Japanese patients with non-small cell lung cancer or gastrointestinal cancer and cancer cachexia (low body mass index <20 kg/m2, involuntary weight loss >2% in the past 6 months, and anorexia). Patients were given 100 mg of anamorelin once daily for up to 24 weeks. The primary endpoint was composite clinical response (CCR) at 9 weeks, defined as a ≥5% increase in body weight from baseline, a ≥5-point increase in the 2-item Anorexia Symptom Scale score on the Anorexia/Cachexia Treatment Functional Assessment, and survival.

Trial results: 71 patients were eligible and enrolled. The mean and standard deviation of age and BMI were 71.0±8.2 years and 17.47±1.48 kg/m2 respectively. The CCR rate at 9 weeks was 25.9%, reaching the primary endpoint. Improvements in weight and anorexia were long-lasting and were accompanied by improvements in the patient's overall impression of changes in appetite/eating-related symptoms and overall condition.

Adverse drug reactions occurred in 37 of 101 treated patients (36.6%), the most common being increased glycosylated hemoglobin, constipation, and peripheral edema.

Conclusion: Anamorelin improved body weight and anorexia-related symptoms in patients with cancer cachexia and low BMI, with durable efficacy and good safety and tolerability.

Recommended related articles:

References

Naito T, Uchino J, Kojima T, Matano Y, Minato K, Tanaka K, Mizukami T, Atagi S, Higashiguchi T, Muro K, Takayama K, Furuse J, Morishima E, Takiguchi T, Tamura K. A multicenter, open-label, single-arm study of anamorelin (ONO-7643) in patients with cancer cachexia and low body mass index. Cancer. 2022 May 15;128(10):2025-2035. doi: 10.1002/cncr.34154. Epub 2022 Feb 23. PMID: 35195274; PMCID: PMC9303784.